A detailed history of Engineers Gate Manager LP transactions in Grifols Sa stock. As of the latest transaction made, Engineers Gate Manager LP holds 40,200 shares of GRFS stock, worth $349,740. This represents 0.01% of its overall portfolio holdings.

Number of Shares
40,200
Previous 27,780 44.71%
Holding current value
$349,740
Previous $175,000 103.43%
% of portfolio
0.01%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$6.28 - $9.38 $77,997 - $116,499
12,420 Added 44.71%
40,200 $356,000
Q2 2024

Aug 14, 2024

BUY
$6.27 - $7.7 $174,180 - $213,906
27,780 New
27,780 $175,000
Q4 2023

Feb 14, 2024

BUY
$7.71 - $11.56 $137,307 - $205,872
17,809 Added 118.17%
32,880 $380,000
Q3 2023

Nov 14, 2023

SELL
$8.91 - $10.91 $87,906 - $107,638
-9,866 Reduced 39.56%
15,071 $137,000
Q2 2023

Aug 14, 2023

BUY
$7.14 - $9.29 $178,050 - $231,664
24,937 New
24,937 $228,000
Q2 2022

Aug 15, 2022

SELL
$10.6 - $13.28 $154,018 - $192,958
-14,530 Reduced 55.25%
11,770 $140,000
Q1 2022

May 16, 2022

BUY
$10.37 - $12.73 $272,731 - $334,799
26,300 New
26,300 $307,000
Q1 2021

May 17, 2021

SELL
$15.15 - $19.78 $202,252 - $264,063
-13,350 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$16.86 - $19.67 $78,230 - $91,268
-4,640 Reduced 25.79%
13,350 $246,000
Q3 2020

Nov 16, 2020

SELL
$15.4 - $20.16 $190,806 - $249,782
-12,390 Reduced 40.78%
17,990 $312,000
Q2 2020

Aug 17, 2020

BUY
$18.24 - $21.45 $175,468 - $206,349
9,620 Added 46.34%
30,380 $554,000
Q1 2020

May 15, 2020

BUY
$16.28 - $25.63 $159,381 - $250,917
9,790 Added 89.24%
20,760 $418,000
Q4 2019

Feb 14, 2020

BUY
$19.57 - $23.52 $214,682 - $258,014
10,970 New
10,970 $255,000

Others Institutions Holding GRFS

About Grifols SA


  • Ticker GRFS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 678,910,976
  • Market Cap $5.91B
  • Description
  • Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...
More about GRFS
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.